Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK ad review

This article was originally published in The Tan Sheet

Executive Summary

The UK's Medicines & Healthcare products Regulatory Agency will review promotional materials for all newly licensed medicines before the advertisements are run, the agency announces Nov. 8. While MHRA previously only reviewed ads for some new ads based on risk, vetting advertising material on all new drugs allows the agency to "provide an additional safeguard to ensure that healthcare professionals and the public are not misled." Review time for promotional materials is expected to last between three and six months "but could take longer should any problems be identified," the agency stated. In the U.S., direct-to-consumer advertising guidelines released in August by the Pharmaceutical Research & Manufacturers of America called for manufacturers to submit advertising materials to FDA prior to launch (1"The Tan Sheet" Aug. 22, 2005, p. 7). EU legislation prohibits direct-to-consumer advertising for conditions including insomnia, diabetes and other metabolic diseases, serious infectious diseases including HIV-related diseases and tuberculosis...

You may also be interested in...

PhRMA Guidelines May Redraw Line Between DTC, OTC Advertising

Pfizer direct-to-consumer prescription drug ads will "clearly indicate... that the medicine is a prescription medicine," the firm said in an Aug. 11 announcement of planned DTC changes

Biocon Biologics Refreshes Management

Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.

Optibac Launches Natural Children’s Probiotic Immunity Supplement In Sustainable Pack

The UK's Optibac responds to sustainability and naturals trends with an all-in-one immunity and gut health food supplement especially designed for children.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts